MannKind | 销售和管理费用

Selling And Administration Expenses 更改 日
Adma Biologics USD 16.22M 1.03M 2023-12
Dynavax Technologies USD 39.79M 2.63M 2023-12
Eli Lilly USD 1.92B 120.7M 2023-12
Halozyme Therapeutics USD 37.61M 2.34M 2023-12
Insmed USD 89.53M 1.1M 2023-12
MannKind USD 20.54M 3.44M 2023-12
Novo Nordisk DKK 14.08B 1.34B 2023-09
Pfizer USD 4.47B 1.27B 2023-12
Xencor USD 15.48M 2.98M 2023-12



MannKind 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Apr 2024.